You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
|
|---|---|
| Published in |
BMC Cancer, February 2012
|
| DOI | 10.1186/1471-2407-12-58 |
| Pubmed ID | |
| Authors |
Atil Bisgin, Aysegul Kargi, Arzu D Yalcin, Cigdem Aydin, Deniz Ekinci, Burhan Savas, Salih Sanlioglu |
| Abstract |
Colorectal cancer is the third most common cancer and the third leading cause of cancer-related death. Bevacizumab is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancer. The parameters of RECIST (Response Evaluation Criteria for Solid Tumors) are not adequate to detect important treatment effects and response. Our goal was to evaluate the possibility of using sTRAIL (serum-soluble TNF-related apoptosis-inducing ligand) and VEGF as markers of treatment efficacy and prognosis in patients with metastatic colon cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 6% |
| Unknown | 17 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 22% |
| Student > Bachelor | 3 | 17% |
| Student > Ph. D. Student | 3 | 17% |
| Student > Master | 1 | 6% |
| Other | 1 | 6% |
| Other | 2 | 11% |
| Unknown | 4 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 22% |
| Biochemistry, Genetics and Molecular Biology | 3 | 17% |
| Unspecified | 1 | 6% |
| Immunology and Microbiology | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Other | 2 | 11% |
| Unknown | 6 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2012.
All research outputs
#20,154,661
of 22,662,201 outputs
Outputs from BMC Cancer
#6,480
of 8,239 outputs
Outputs of similar age
#223,979
of 247,589 outputs
Outputs of similar age from BMC Cancer
#64
of 75 outputs
Altmetric has tracked 22,662,201 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,239 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,589 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.